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Abstract
Background: High-throughput technology allows for genome-wide measurements at different molecular levels for
the same patient, e.g. single nucleotide polymorphisms (SNPs) and gene expression. Correspondingly, it might be
beneficial to also integrate complementary information from different molecular levels when building multivariable
risk prediction models for a clinical endpoint, such as treatment response or survival. Unfortunately, such a
high-dimensional modeling task will often be complicated by a limited overlap of molecular measurements at
different levels between patients, i.e. measurements from all molecular levels are available only for a smaller
proportion of patients.
Results: We propose a sequential strategy for building clinical risk prediction models that integrate genome-wide
measurements from two molecular levels in a complementary way. To deal with partial overlap, we develop an
imputation approach that allows us to use all available data. This approach is investigated in two acute myeloid
leukemia applications combining gene expression with either SNP or DNA methylation data. After obtaining a sparse
risk prediction signature e.g. from SNP data, an automatically selected set of prognostic SNPs, by componentwise
likelihood-based boosting, imputation is performed for the corresponding linear predictor by a linking model that
incorporates e.g. gene expression measurements. The imputed linear predictor is then used for adjustment when
building a prognostic signature from the gene expression data. For evaluation, we consider stability, as quantified by
inclusion frequencies across resampling data sets. Despite an extremely small overlap in the application example with
gene expression and SNPs, several genes are seen to be more stably identified when taking the (imputed) linear
predictor from the SNP data into account. In the application with gene expression and DNA methylation, prediction
performance with respect to survival also indicates that the proposed approach might work well.
Conclusions: We consider imputation of linear predictor values to be a feasible and sensible approach for dealing
with partial overlap in complementary integrative analysis of molecular measurements at different levels. More
generally, these results indicate that a complementary strategy for integrating different molecular levels can result in
more stable risk prediction signatures, potentially providing a more reliable insight into the underlying biology.
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Background
When molecular measurements are obtained from
patients in a clinical cohort by high-throughput tech-
niques, the number of covariates is typically much larger
than the number of observations. There are established
statistical techniques for linking measurements from a
single molecular level to clinical endpoints such as sur-
vival. In particular, techniques for regularized estimation
of regression models, such as the lasso [1] or compo-
nentwise likelihood-based boosting [2] can automatically
select potentially important molecular entities.
In more recent studies, microarray and sequencing
technologies are used to measure a large number of
patients’ characteristics at different molecular levels
simultaneously. For example, the data that motivated us
to develop an integrative analysis strategy comes from a
study on acute myeloid leukemia (AML) patients with sin-
gle nucleotide polymorphism (SNP) microarray measure-
ments [3] and microarray-based gene expression profiling
(GEP) data [4, 5]. Corresponding to what might be consid-
ered the natural biological order, we propose a sequential
complementary strategy in the following as a tool for inte-
grative data analysis, which first extracts information from
the SNP data, and then looks for additional prognostic
information in the gene expressionmeasurements. Ideally,
the knowledge obtained from the SNP data should help
to stabilize selection of genes for a prognostic signature
based on the microarray-based GEP data.
Such an integrative analysis is complicated by having a
partial overlap, i.e. not all molecular levels are measured
for all patients. For example in our AML application, there
are some patients with measurements available from both
genome-wide measurement platforms, but some patients
have measurements from only one single molecular level,
either from the microarray-based GEP or from the SNP
microarray. An indication that this is a more widespread
problem is provided, e.g. by the data available in the Can-
cer GenomeAtlas (TCGA) (https://tcga-data.nci.nih.gov/
tcga/). Due to a multitude of reasons (assay failure, sample
quality issues, changes in measurement platforms, etc.),
not every type of measurement is available for each indi-
vidual. As a straightforward complete case analysis would
discard much of the available information, partial overlap
has to be addressed before an integrative analysis can be
performed.
We propose a corresponding imputation approach that
fits with our sequential integrative analysis strategy. In
particular, we will show that our sequential strategy does
not require imputation at the SNP level, but only impu-
tation of a linear predictor that based on the SNPs.
Estimation for the prognostic models, i.e. the linear pre-
dictors, as well as for an imputation regression model
will be performed by componentwise likelihood-based
boosting [2, 6].
While a multitude of statistical techniques have been
developed for building models that predict a clinical
endpoint based on high-dimensional data from a single
molecular level, combined analysis of multiple genome-
wide data sets relating to clinical endpoints has received
less attention. Integrative analysis of several platforms
using multivariable techniques such as clustering [7] or
principle components [8, 9] is often performed for assess-
ing the relations between various levels but without taking
a clinical endpoint into account. In contrast, the pro-
posed sequential complementary strategy directly links
the different molecular levels of information to a clinical
endpoint, such as time to death, while taking established
clinical predictors into account.
The paper is organized as follows: The following section
introduces two applications, where a prognostic model is
wanted for patients with acute myeloid leukemia (AML),
and then details the proposed sequential complemen-
tary strategy, including a stepwise estimation procedure
and an imputation approach. In the results section, the
sequential complementary strategy is illustrated for SNP
and microarray-based gene expression data in the first
AML application and for methylation and gene expres-
sion sequencing data in the second AML application. In
the subsequent section, the results are discussed andmore
general concluding remarks are provided.
Methods
Acute myeloid leukemia data
Acute myeloid leukemia (AML), the most common acute
leukemia in adults, represents a genetically heteroge-
neous disease with respect to clinical outcome, such as
time to relapse or death. Currently, several clinically rel-
evant molecular markers are known that characterize
AML at the molecular level [3]. An integrative analy-
sis of molecular data from different molecular platforms
might help to identify additional molecular subgroups
relevant for the prognosis of AML patients. This is
of particular importance as current AML molecular-
based classification based on single molecular lev-
els are not robust enough to predict the prognosis
for AML patients, due to the heterogeneity within
AML [10].
In the two motivating data examples considered in the
following, the time-to-event clinical endpoint of interest
is survival (relapse free survival (RFS), i.e. time to relapse
or death from any cause, whatever happens first, in a first
application, and overall survival in a second application).
In the first application, measurements from two different
molecular levels, single nucleotide polymorphism (SNP)
information from microarrays [3] and microarray-based
gene expression (GEP) data [4, 5] are available for devel-
oping a prognostic signature. The data are included in
Additional files 1, 2 and 3. Specifically, there are 390443
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SNP features for 308 AML patients and 19088 gene
expression features for 319 AML patients, with an over-
lap of 26 patients where both types of measurements are
available. During follow-up time, 154 AML patients with
SNPmeasurements and 196 AML patients with GEPmea-
surements had a relapse or died. As a benchmark for
prognostic models, the established predictors age, white
blood cell count (WBC), somatically acquired mutations
in nucleophosmin 1 (NPM1) and fms-related tyrosine
kinase 3 internal tandem-duplication (FLT3− ITD) genes
as well as a cytogenetic risk group factor are available for
all AML patients.
The second application, considers methylation and gene
expression sequencing data as well as clinical information
from the Cancer Genome Atlas (TCGA). Data sets were
not available for all individuals on all platforms because
of same availability, assay failure and quality issues. DNA
methylation information for 194 patients were gener-
ated from the Illumina Infinium HumanMethylation450
BeadChip for bisulfite-treated DNA. There are measure-
ments of methylation status for 485577 CpG sites for
each patient. After pre-processing steps, 396065 methyla-
tion features remain. Twelve samples were excluded due
to missing outcome data. Of these 182 AML patients,
118 AML cases died during their follow-up. In addition
to methylation measurements, there are gene expression
sequencing data (RNA-seq) for 179 AML cases, compris-
ing 20442 RNA-seq measurements per patient. Ten of 179
AML cases were excluded due to missing outcome infor-
mation. Asmentioned above, death is the event of interest.
This event was observed in 108 out of 169 AML cases.
Since our focus lies on the integrative analysis of molec-
ular measurements at different levels while taking clinical
predictors into account, two clinical covariates (sex and
age at initial pathological diagnosis) available for all AML
cases are investigated. In total, there is an overlap of 166
AML cases with information from both types of molecu-
lar levels. The data can be downloaded directly from the
TCGA website (https://tcga-data.nci.nih.gov/tcga/).
Sequential complementary strategy
In the following, we will propose an approach for
integrative analysis in both applications above, the first
considering microarray-based gene expression profiling
(GEP) and SNP data, and the second considering gene
expression sequencing (RNA-seq) and methylation data,
to illustrate the general applicability of our proposal. Yet,
notation and explanation will focus on the combination
of GEP and SNP data (first AML application) in the
following, for simplicity.
Specifically, we propose a sequential complementary
strategy for an integrative analysis of different molecu-
lar levels with potentially partial overlap in the biological
samples. We first provide two risk prediction models, for
the SNP data and the GEP data respectively, followed
by an imputation approach for dealing with partial over-
lap, and finally the technical details of model fitting and
a brief discussion of the order in which SNP and GEP
data are considered for modeling. A flowchart describing
the sequential complementary strategy based on the step-
wise procedure and the imputation approach is given in
Fig. 1.
Censored time to event data, e.g. as in the time to
relapse AML application above, are typically given as
triples (ti, δi, zi), i = 1, . . . n, where ti is the observed time
for an individual, which is given by ti = min(Ti,Ci), with
event time Ti and censoring time Ci. The event indica-
tor δi = I(Ti ≤ Ci), with indicator function I(.), takes
value 1 if its argument is true, and 0 otherwise. The covari-
ate vector zi = (zi1, . . . , zip)′ comprises covariates known
at baseline. We assume that it can be partitioned into
a vector xclini of d clinical covariates, a vector xSNPi of k
SNP covariates, and a vector xGEPi of q gene expression
covariates. In the following, the vectors zSNPi and zGEPi
are assumed to comprise the SNP and microarray-based
GEP covariates respectively, in addition to the clinical
covariates.
A common regression model for time to event data is
the Cox proportional hazardmodel [11]. For the SNP data,





= hSNP0 (t) exp(ηclini + ηSNPi )
= hSNP0 (t) exp
(







The hazard hSNP(t|zSNPi ) is the instantaneous risk of
observing an event at time t given survival until t con-
ditional on the clinical and SNP covariates. It is mod-
eled by the unspecified baseline hazard hSNP0 (t) and
the linear predictors ηclini and ηSNPi for the clinical
and SNP covariates with parameter vectors αSNP =
(αSNP1 , . . . ,αSNPd )′ and γ SNP = (γ SNP1 , . . . , γ SNPk )′. Subse-
quently, the parameters γ SNP will be estimated by a reg-
ularized approach for obtaining many estimates equal to
zero and only a small set of signature SNPs with non-zero
estimates. The parameters αSNP are estimated using stan-
dard maximum (partial) likelihood techniques without
penalization.
This Cox proportional hazard model for the SNP data
can be used for guiding the fit of a Cox proportional
hazardmodel for themicroarray-based GEP data for iden-
tifying genes whose expression provides prognostic infor-
mation beyond the SNP data. In particular, we propose to
use regularized estimation for fitting a model
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Fig. 1 Flowchart describing the sequential complementary strategy based on a stepwise procedure (notation focuses on the first AML application
combining GEP and SNP data). Established clinical predictors (clin) that need to be adjusted for are considered as mandatory in the stepwise
procedure based on componentwise likelihood-based boosting. Important clinical predictors are available for all AML cases. The SNP signature
(ηˆSNPi ) including the known SNP signature (overlap samples) from model (1) and the predicted SNP signature (non-overlap samples) considering
continuous response linear regression (3) as prediction technique is incorporated as fixed offset in model (2) for the microarray-based GEP data
where hGEP0 (t) is the unspecified baseline hazard and
parameter vector βGEP = (βGEP1 , . . . ,βGEPq )′. For extract-
ing the complementary information from the GEP data
by adjusting for the effects of the SNP data in the model
for the GEP data, ηˆSNPi is incorporated as a fixed off-
set obtained from the estimates in model (1) (see Fig. 1,
step 2). Note that the parameter vector αGEP for the
clinical covariates is different from αSNP in model (1),
as it is now used to take the clinical covariates into
account when considering gene expression instead of SNP
measurements. In particular, we will use unregularized
estimation, as detailed in the section on estimation below,
for maximally adjusting for the effect of clinical effects in
both prognostic models, i.e. in that based on the SNPs
and also in that based on GEP measurements. The reason
for this is that we are interested in information from the
SNP and GEP data that is not already contained in clinical
covariates.
Imputation approach and linking model
To address a partial overlap, we propose imputation of
the linear predictor ηˆSNPi , called SNP signature in the
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following. After values for this linear predictor have been
imputed for individuals without SNP measurements all
available observations can be used when fitting model (2).
To impute the information from the SNP microar-
ray for the individuals with measurements from the
microarray-based GEP data only, a linking model is fitted.
Using the samples withmeasurements available from both
sources, i.e. SNPs and GEP, we consider the SNP signa-
ture ηˆSNPi as a continuous response in a regression model
with gene expression features as covariates (see Fig. 1,
step 1b). Established clinical predictors again receive a
separate parameter vector, to be estimated unregularized,
to adjust out any effect that might have been introduced
by estimation of their effect in model (1).
Specifically, we propose a continuous response linear




link + x′GEPi β link + i, (3)
where i is the error term. The parameter vector β link =
(β link1 , . . . ,β linkq ) for the GEP covariates is different from
βGEP in model (2), as it now reflects the information that
can be extracted from the GEP covariates for predicting
the SNP signature ηˆSNPi . Using the estimated parameters
from the model above, the SNP signature is predicted for
the non-overlap samples and incorporated inmodel (2) for
the GEP data (see Fig. 1, step 2).
Based on the imputation approach, the sequential
complementary strategy does not have to assemble all
molecular measurements into a single model. Therefore,
compared to approaches which consider both molecu-
lar levels in parallel [12], the sequential strategy has the
advantage to take specific characteristics of the differ-
ent molecular levels into account, e.g. biological relations
between SNP and microarray-based GEP data.
Estimation by componentwise likelihood-based boosting
The parameters in all three regression models above, i.e.
both risk prediction models (1) and (2) for the SNP and
GEP data respectively, and in the linking model (3), will
be estimated by a regularized approach to avoid overfit-
ting and for selecting a small set of SNPs and genes with
non-zero estimated effects. Specifically, we use a com-
ponentwise likelihood-based boosting approach, which is
available for continuous endpoints [6] as well as for Cox
proportional hazards models [2]. The details are provided
in these references, andwe provide only a brief description
in the following.
Componentwise likelihood-based boosting starts with
estimated parameter vectors equal to zero and builds
up estimates using a stepwise algorithm with a poten-
tially large number of boosting steps. To obtain sparse
fits, as intended in high-dimensional data, only one ele-
ment of the parameter vector is updated in each boosting
step. To identify the element to be updated, a candi-
date model is fitted for each covariate in each boosting
step, comprising only this covariate and a fixed offset
that contains the information from the previous boosting
steps. The parameters in these models are estimated by
a penalized maximum (partial) likelihood approach, and
finally the element to be updated is chosen to be the one
that maximizes the (partial) log-likelihood. Component-
wise likelihood-based boosting can distinguish between
mandatory covariates, which are always included in the
model, e.g. established clinical predictors that need to be
adjusted for, and optional covariates. While the parame-
ters for the optional covariates are estimated as described
above, the parameters for the mandatory covariates are
estimated by standard maximum (partial) likelihood tech-
niques. For estimating the parameters in the three regres-
sion models (1), (2), and (3), the clinical covariates are
treated as mandatory, while the SNP and GEP covariates
are considered as optional, i.e. are subjected to regular-
ization. The main tuning parameter of the boosting algo-
rithm is the number of boosting steps, which is selected by
cross-validation to optimize prediction performance and
to avoid overfitting. The penalty parameter in the penal-
ized (partial) likelihood is of minor importance, as long as
it is large enough.
Ordering of molecular levels for analysis
The proposed strategy integrates data from two molecu-
lar levels with potentially small overlap in the biological
samples, while taking established clinical predictors into
account. The sequential approach is not based on the
assumption of direct links between molecular levels as
both sources are used in different roles. The sequen-
tial order of the different data sources depends on the
underlying question of the integrative analysis. Such an
order can be based on the biological relations, such as
between SNP and microarray-based GEP data or can be
swapped, e.g. first a prognostic model for GEP data could
be fitted, and the linear predictor from this model could
then be used for adjustment in prognostic model build-
ing from the SNP microarray data. While this order could
be considered to be contrary to biological relations, such
analyses could nevertheless be performed. However, the
sequential order should be prespecified before starting the
integrative analysis, to avoid decisionmaking based on the
results.
For the first application with GEP and SNP data, the
SNP microarray data are analyzed first and the results
are used for guiding GEP features that contain informa-
tion beyond what is already provides by the SNPs in the
following, reflecting the biological relation between SNP
and GEP data. For the second application, investigating
gene expression sequencing (RNA-seq) and methylation
data, we consider RNA-seq data first and then analyze
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the methylation data adjusted for RNA-seq effects, thus
potentially better highlighting the signals in the methy-
lation data that are not directly visible in the RNA-seq
measurements.
Results
Application for combining SNP and GEP data
In a first application, we illustrate the proposed approach
for a complementary integrative analysis of SNP and
microarray-based GEP data from AML patients with
respect to relapse free survival. As a reference approach
we fit a risk prediction model for the GEP data with-
out adjusting for the effects of the SNP data. The model
for the reference approach will be estimated again by
componentwise likelihood-based boosting. As criteria for
comparison, we will consider stability of selected signa-
tures, as quantified by resampling inclusion frequencies,
as well as prediction performance.
Model building
For modeling the effects of the SNPs, we use a coding
scheme with two dummy covariates per SNP to distin-
guish between dominant and recessive effects. Minor
allele frequencies are coded as z(1)i(j) = 0 and z
(1)
i(j+1) = 1 for
0, z(1)i(j) = 1 and z
(1)
i(j+1) = 0 for 1 and z
(1)
i(j) = 1 and z
(1)
i(j+1) = 1
for 2 (see Reference [13] for example), i = 1, . . . , 308 and
j = 1, . . . , 390443. Shrunken estimates, as obtained by the
boosting technique, then take the meaning of ’no/small’-
dominant and ’no/small’ recessive effects. The predictors
age, WBC, NPM1 and FLT3 − ITD status as well as a
cytogenetic risk group factor are included as mandatory
covariates in addition to the optional SNP covariates in
componentwise likelihood-based boosting used to obtain
sparse fits from the SNP data.
Twenty-three SNPs are selected for the SNP risk pre-
diction model (1), i.e. they received non-zero estimates.
The estimated coefficient paths of these SNPs are given
in Additional file 3. The vertical line indicates the opti-
mal number of boosting steps as selected via 10-fold
cross-validation. For all subsequent uses of boosting,
the number of boosting steps was also selected via 10-
fold cross-validation. The resulting SNP signature (ηˆSNPi )
includes the most important prognostic information from
the SNP microarray for each of the 308 biological samples
with measurements available from this molecular level.
To address the partial overlap in the biological samples,
imputation of the SNP signature is performed by fitting
linking model (3) for the 26 biological samples using the
GEP features conditioning on the overlap samples. The
same five clinical predictors for adjustment as in risk
prediction model (1) for the SNP data are used as manda-
tory covariates in addition to the optional GEP covariates.
Eight GEP features are selected for the linking model (3)
by boosting with respect to the continuous endpoint, i.e.
the SNP signature. The coefficient paths of these GEP fea-
tures are shown in Additional file 3. Next, imputation by
prediction of the SNP signature is done for the 293 AML
patients with measurements from the microarray-based
GEP only.
To judge the model fit on the overlap samples the mean
squared error is determined by the bootstrap .632+ tech-
nique [14], which is a weighted combination of the appar-
ent error and the bootstrap cross-validation estimate. The
resulting prediction error estimate of 0.13 does not indi-
cate particularly good performance. However, it has to be
considered that the model is based on 26 overlap samples
only and does perform only slightly worse than imputing
the mean value of the SNP signature (prediction error of
0.11 determined by the apparent error). We nevertheless
evaluate in the following whether the resulting imputed
linear predictor might prove useful for adjustment when
considering effects of GEP measurements on relapse-free
survival.
For extracting complementary information from the
GEP data, the SNP signature is incorporated as a fixed off-
set into the risk prediction model (2) using the GEP data.
Risk prediction model (2) is estimated by componentwise
likelihood-based boosting incorporating the same five
mandatory clinical predictors as in risk prediction model
(1) and linking model (3). While thirty-four GEP features
are selected by the sequential complementary strategy,
the reference approach selects twenty-seven GEP fea-
tures. The estimated coefficient paths for the GEP covari-
ates selected by the sequential complementary strategy
and the reference approach, respectively, are shown in
Additional file 4. Twenty-one of the twenty-seven GEP
features selected by the reference approach are also within
the thirty-four GEP features selected by the sequential
complementary strategy. This is, the remaining thirteen
GEP features of the thirty-four GEP features obtained by
the sequential complementary strategy are selected only
when incorporating the (imputed) linear predictor of the
SNP signature as fixed offset in the risk prediction model
together with the GEP data. Therefore, complementary
information can be extracted from the gene expression
measurements after using the effects from the SNP data
for guiding the GEP data.
Some IMAGE (Integrated Molecular Analysis of
Genomes and their Expression) cDNA clones are not
linked to genes, but rather represent expressed sequence
tags (ESTs), whereas other IMAGE clones represent anno-
tated genes. Note that single genes can be represented by
several IMAGE clones, similar to Affymetrix arrays where
single genes are often covered by numerous probe sets.
Variable selection stability
Stability quantified by resampling techniques is consid-
ered to judge model quality. The underlying idea is to
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perform model building (including variable selection) in
several resampling data sets and to consider for each
covariate the proportion of final models derived from the
resampled data sets where it has been selected. See for
example [15, 16] for more details of quantifying signature
stability by resampling inclusion frequencies. However,
stability criteria have also been applied to enhance and
to improve existing methods for variable selection by
supporting consistent structure estimation and optimiz-
ing variable selection methods called stability selection
[17]. Selection stability has even be suggested obtain-
ing the false discovery rates [17]. We rather use stability
as a criterion for comparing the sequential complemen-
tary strategy and the reference approach to investigate
model structure and to draw inferences from the statistical
strategy on the relation between the different molecu-
lar sources. Therefore, the aim of this work is not to
optimize neither the sequential complementary strategy
nor the established risk prediction model used as refer-
ence approach. Stability of a selected model is used as
an evaluation criterion to judge a given variable selec-
tion procedure or to compare different variable selection
procedures [15].
In the following, feature selection of the molecular enti-
ties is performed for each of 100 resampling data sets, i.e.
the sequential complementary strategy as well as the refer-
ence approach are applied. Resampling can be performed
with replacement, corresponding to the bootstrap, or
without replacement, i.e. subsampling. However, resam-
pling with replacement introduces a bias that will affect
approaches that select a tuning parameter, e.g. the num-
ber of boosting steps in each resampling data set, which
is selected according to prediction performance to avoid
overfitting using 10-fold cross-validation. See Reference
[18] for more details on this bias. Therefore, we use sub-
sampling in the following for generating data sets of size
0.632n. The resampling inclusion frequency algorithm is
illustrated in Additional file 5.
In the first AML application, we consider the inclusion
frequency for each gene selected in the original GEP data
by the sequential complementary strategy (33 genes com-
pared to 34 IMAGE clones) and by the reference approach
(24 genes compared to 27 IMAGE clones) shown in Fig. 2.
Genes selected by the sequential complementary strategy
as well as by the reference approach in the original GEP
data are displayed in black, genes selected by the reference
approach only are displayed in red and genes selected by
the sequential complementary strategy only are displayed
in green. Figure 2 shows a varying inclusion frequency
for these genes selected from both strategies in the orig-
inal GEP data. There are at least some genes selected
by both strategies that have an increased inclusion fre-
quency in the sequential strategy. For some other genes
there is a decreased inclusion frequency. As an underlying
pattern, genes that are selected in the original GEP data
by the reference approach only (indicated by red) have a
systematically smaller inclusion frequencies when using
the sequential complementary strategy. Reversely, genes
that are selected on the original GEP data by the sequen-
tial complementary strategy also have increased inclusion
frequencies when using this approach. There are even
four genes selected only by the sequential complementary
strategy in the original data which received an inclusion
frequency greater than 10 % only when using the sequen-
tial complementary strategy. These systematic differences
in the inclusion frequencies indicate that different lists of
genes are stably selected when using the reference and the
sequential complementary approach, respectively.
Specific components of the sequential complementary
strategy, such as boosting, can be replaced by other mod-
eling techniques. In particular, by penalized regression
approaches, such as lasso [1]. To carry out a compar-
ison of the results obtained from the sequential com-
plementary strategy based on boosting and other mod-
eling approaches, the risk prediction model (2) for the
microarray-based GEP data was also estimated by the
lasso. Within the stepwise procedure of the sequential
strategy, risk predictionmodels (1) and (3) will still be esti-
mated by componentwise boosting. Nineteen genes are
selected by the reference approach based on lasso and
twenty-eight genes are selected by the sequential com-
plementary strategy where risk prediction model (2) is
estimated by lasso. The inclusion frequency patterns for
the genes are very similar to those resulting from compo-
nentwise boosting (Additional file 6).
Prediction performance
To investigate whether the sequential complementary
strategy provides reasonable prediction performance and
to additionally verify that the extracted complementary
information from the GEP measurements after adjusting
for the effects from the SNP microarray is not only due to
noise, the prediction performances of the sequential and
reference approach are investigated. For evaluating the
prediction performance, the Brier score [19], i.e. a time-
dependent measure of prediction error, is used resulting
in a prediction error curve. Prediction error estimates are
obtained by the bootstrap .632+ technique [18, 20, 21]. As
a conservative reference for prediction performance the
Kaplan-Meier benchmark that does not use any covariate
information is used. The performances of the sequential
and the reference approach are furthermore compared to
a Cox model that includes only the five clinical predictors
as in risk prediction models (1), (2) and (3).
Figure 3 shows the .632+ prediction error estimates
for the sequential complementary strategy (dashed red
curve) and the reference approach (solid blue curve). In
addition, the estimated prediction error curve for the
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Fig. 2 Resampling inclusion frequencies for the genes selected by the sequential as well as by the reference approach (black), genes selected only
by the reference approach (red) and genes selected only by the sequential complementary strategy (green) from the GEP data (first AML
application). The inclusion frequencies for these genes concerning the reference approach are displayed by squares and the inclusion frequencies
for these genes concerning the sequential complementary strategy are displayed by dots. Reference approach and sequential complementary
strategy are estimated by componentwise boosting
Fig. 3 Prediction error curves for the first AML data application example. Bootstrap .632+ prediction error curves estimates for sequential
complementary strategy, i.e. boosting including SNP information for adjustment (dashed red curve) and for the reference approach, i.e. boosting
without including SNP information (solid blue curve). The Kaplan-Meier benchmark is indicated by the dashed-dotted gray curve and the Cox model
is given by dotted black curve
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Cox model, that includes only the five important clinical
predictors (dotted black curve), is displayed. The Kaplan-
Meier benchmark (grey dashed-dotted curve) is given as
reference. All prediction error curve estimates are seen
to improve over the Kaplan-Meier benchmark. The pre-
diction performances of the sequential complementary
strategy as well as of the reference approach also improve
over the Cox model. It is seen that the performance of
the sequential complementary strategy is roughly similar
to prediction performance of the reference approach at
early times. However, the sequential complementary strat-
egy seems to improve over the reference approach for later
time points. Thus, the imputed linear predictor seems to
contain useful information.
Figure 4 shows boxplots of the integrated prediction
error curves, i.e. the .632+ prediction error estimate is
calculated separately for each single bootstrap sample
to evaluate the variability of the prediction performance
underlying the estimates in Fig. 3. The conclusions drawn
from Fig. 3 hold, even when variability is taken into
account. The sequential complementary strategy based
on 26 overlap samples implies better prediction perfor-
mance compared to the reference approach and both
outperform the Kaplan-Meier benchmark as well as the
Cox model.
Effect of the overlap size
One might expect that the relative size of overlap has a
considerable impact on the performance of the sequential
complementary strategy. Therefore, in the first AML
application, we systematically decreased the size of over-
lap from 26 to 10 biological samples. This is done by ran-
domly drawing 15 and 10 biological samples, respectively,
from the 26 overlap samples with available measurements
from both molecular data in parallel. The remaining
biological samples, which are not randomly drawn, are
treated as if they would have measurements from the GEP
data only. Figure 4 shows the resulting prediction perfor-
mance. For 15 overlap samples there is still a reasonable
performance still implying better prediction performance
compared to the reference approach. However, an overlap
size of 10 biological samples results in very unfavorable
prediction performance compared to the performance
of the reference approach and of the sequential strategy
based on 26 and 15 biological samples, respectively.
In addition, to examine the effect of the overlap size
on the performance of the linking model (3) used for
data imputation, the mean squared error is determined by
the bootstrap .632+ technique. The resulting prediction
error estimates for the varying overlap sizes are displayed
in Additional file 7. The prediction performance of the
null model, i.e. imputing the mean value of the SNP sig-
nature, determined by the apparent error is considered
as a reference. Generally, the linking model (3) does not
exhibit good prediction performance. In particular, for
all varying overlap sizes the linking model results in per-
formance worse than the intercept model. Nevertheless,
the resulting imputation still enables somewhat improved
prediction performance with respect to the clinical end-
point, as seen in Fig. 4.
Fig. 4 Variability of the .632+ prediction error estimates in the first AML application based on varying overlap sizes of 26, 15 and 10 biological
samples, respectively. Integrated prediction error curve estimates for the Cox model, the reference approach and the sequential complementary
strategy. The performance of the Kaplan-Meier benchmark is indicated by a horizontal line
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Different order of molecular levels
A swapped order of molecular levels within the sequen-
tial complementary strategy is investigated in the first
AML application by analyzing first the GEP data and using
the corresponding linear predictor for adjustment in a
risk prediction model based on the SNP microarray data.
Boxplots of the resulting integrated prediction error esti-
mates are shown in Additional file 8. There also is a slight
improvement in prediction performance of the sequential
complementary strategy (swapped order) compared to the
reference approach, i.e. SNPmodel without includingGEP
information for adjustment. Thus, there is no firm conclu-
sion with respect to biological relations. Correspondingly,
the more pronounced improvement in prediction perfor-
mance when using the biologically more plausible order
in the sequential strategy (Fig. 4) might not just be due to
chance.
Application for combiningmethylation and gene
expression sequencing (RNA-seq) data
In the second AML application, we consider integration
of methylation and gene expression sequencing measure-
ments with respect to overall survival. For the methy-
lation data, we use M-values, which are simply a trans-
formation of the beta value [22]. The latter is a number
between zero and one that measures the percentage of
methylation. The RNA-seq data are normalized using
the DESeq normalization proposed by [23]. The mea-
surements are log-transformed, following the suggestion
in [24]. In the following, the sequential order is chosen
such as to first extract information from the RNA-seq
measurements and then to use the results to better high-
light remaining signals in the methylation data. There
is an overlap of about 92 % in the biological samples.
Imputation of the RNA-seq signature is performed by
fitting a linking model (3) using methylation data con-
ditioning for 166 overlap samples. The resulting predic-
tion error estimate of 0.25 determined by the bootstrap
.632+ technique does indicate good prediction perfor-
mance as the linking model improves the benchmark
model by imputing the mean value of the RNA-seq signa-
ture (prediction error of 0.93 determined by the apparent
error). In addition, the effect of the size of overlap on
the performance of the sequential complementary strat-
egy is investigated by systematically decreasing the size
from about 92 % to about 18 %. Specifically, this is done
by drawing 100, 50 and 30 biological samples, respec-
tively, from the 166 overlap samples. Even more pro-
nounced as in the first application, the prediction perfor-
mance of the sequential complementary strategy improves
over the reference approach (Fig. 5). In particular, a
considerable advantage remains even for rather small
overlap sizes.
Discussion
Recently, a multitude of techniques have become avail-
able to obtain genome-wide data sets at various molecular
levels. Integrative analysis of such molecular data from
different platforms might provide additional insight. For
example, our motivation for the integrative analysis of var-
ious molecular levels came from an application with AML
patients, where there is still huge unexplained heterogene-
ity within the defined molecular subtypes based on clini-
cally relevant molecular marker from single genetic data.
Our aim was to develop a strategy for integrating multiple
genome-wide data sets in a complementary way, despite
a potentially small overlap in the biological samples. This
also is a potential alternative to parallel approaches which
incorporate all information in once but require availability
of all sources for all individuals. In the first AML applica-
tion, we considered measurements SNP microarrays and
microarray-based gene expression (GEP) measurement.
Both molecular data sets need to be combined into an
integrative data analysis for identifying prognostic signa-
tures. In the second application, we considered integrative
analysis for gene expression sequencing (RNA-seq) and
methylation measurements.
We developed a sequential complementary strategy
that is a stepwise procedure based on componentwise
likelihood-based boosting. The stepwise procedure ana-
lyzes first one molecular level individually and then the
results from the first molecular data set are used for guid-
ing the model for another molecular data set. Specifically,
this means that the sequential complementary strategy is
designed for extracting complementary information from
the second molecular data set by adjusting for the effects
from the first molecular level in the model for the sec-
ond data set. The developed strategy is not based on the
assumption of direct links between molecular levels. Such
a sequential complementary strategy can take the biologi-
cal hierarchies between the different molecular levels into
account, e.g. focusing on GEP features that provide infor-
mation beyond SNPs, or the order can be swapped. Also,
more than two sources could potentially be investigated
by considering several linear predictors.
To assess the proposed sequential complementary strat-
egy we considered a reference approach, where a prog-
nostic model was fitted based on the GEP data without
adjusting for the effects of the SNP microarray data in
the first application. Twenty genes were identified by the
sequential as well as by the reference approach. In addition
to the twenty genes, thirteen genes were identified by the
sequential complementary strategy only. This might be
an instance where the sequential complementary strategy
provides molecular features that were not selected by a
risk prediction model considering a single molecular data
set only. When considering resampling inclusion frequen-
cies for judging signature stability, genes selected by the
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Fig. 5 Variability of the .632+ prediction error estimates in the second AML application based on varying overlap sizes of 166, 100, 50 and 30
biological samples, respectively. Integrated prediction error curve estimates for the Cox model, the reference approach and the sequential
complementary strategy (verification example). The performance of the Kaplan-Meier benchmark is indicated by a horizontal line
sequential complementary strategy in the original GEP
data also received larger inclusion frequencies when using
this strategy, as compared to the reference approach, fur-
ther underlining that our strategy results in a structurally
different stable set of prognostic genes.
Importantly, in the first application, the list of genes
identified from the GEP data after adjusting for the effects
from the SNP data was biologically meaningful including
both genes previously reported to be associated with out-
come in AML such as DNAL2 [4]. Similarly, NDFIP2 rep-
resents another interesting leukemia relevant candidate
gene as it is an important element of the ubiquitin-
proteasome system (UPS) that plays an essential role in
the homeostasis of cellular protein traffic and degrada-
tion, regulating cell fate, together with autophagy and
apoptosis. While disruption of UPS is essential for leuke-
mogenesis, recently NDFIP2 was found deregulated and
associated with blast counts in AML [25]. In addition,
the list contained novel candidates so far not linked to
AML inmore detail, such as, e.g.NR2C2 (nuclear receptor
subfamily 2, group C, member 2) coding for a ligand-
activated transcription factor that is an important repres-
sor of nuclear receptor signaling pathways such as retinoic
acid receptor, which is crucial for the differentiation of
myeloid cells. Similarly, the PRKCE (protein kinase C,
epsilon) gene represents an interesting candidate belong-
ing to the serine- and threonine-specific protein kinases
that phosphorylate a wide variety of protein targets and
are known to be involved in diverse cellular signaling
pathways also important in the differentiation of myeloid
cells.
In the second AML application, improved prediction
performance compared to a reference approach indicated
that the proposed imputation strategy works well for dif-
ferent overlap sizes, in particular still providing some gain
even for a small overlap.
Conclusion
The sequential strategy was developed to resolve the prob-
lem of the complementary integrative analysis of different
molecular data sets with potentially partial overlap in
the biological samples. It provided promising results in
two applications to data from AML patients. While we
explored it in the context of these specific applications,
it does not depend on these examples and can also be
applied to similar problems. Specific components within
the stepwise procedure, such as componentwise boost-
ing, might be replaced by other modeling approaches, e.g.
lasso, thus providing a more general strategy. However,
such modifications need further research in the future.
Naturally, as the results from the AML application have
only exemplary character, further research is needed for
refining and validating of the proposed approach to arrive
at such a more general strategy. However, the present
results already indicate that such an approach might be
promising.
Hieke et al. BMC Bioinformatics  (2016) 17:327 Page 12 of 13
Additional files
Additional file 1: Single nucleotide polymorphism (SNP) microarray data.
SNP data underlying the finding in this article. (Rdata 50688 kb)
Additional file 2: Microarray-based gene expression profiling (GEP) data.
GEP data underlying the finding in this article. (Rdata 44977 kb)
Additional file 3: Coefficient paths of SNP and GEP measurements (first
AML application example). Parameter estimates obtained from
componentwise likelihood-based boosting for the SNP microarray data
(left panel) and parameter estimates obtained from componentwise
likelihood-based boosting for the microarray-based GEP data conditioning
on the overlap samples (right panel), plotted against the number of
boosting steps. (PDF 64 kb)
Additional file 4: Coefficient paths of the GEP features selected from the
sequential complementary strategy and from the reference approach (first
AML application example). Parameter estimates obtained from sequential
complementary strategy for the microarray-based GEP data (left panel) and
parameter estimates obtained from the reference approach for the
microarray-based GEP data (right panel), plotted against the number of
boosting steps. (PDF 74 kb)
Additional file 5: Resampling inclusion frequency algorithm. Resampling
inclusion frequency setup investigated to evaluate model stability.
(PDF 77 kb)
Additional file 6: Resampling inclusion frequency patterns based on
lasso (first AML application example). Resampling inclusion frequencies for
the genes selected by the sequential as well as by the reference approach
(black), genes selected only by the reference approach (red) and genes
selected only by the sequential complementary strategy (green) from the
GEP data (first AML application example). The inclusion frequencies for
these genes concerning the reference approach are displayed by squares
and the inclusion frequencies for these genes concerning the sequential
complementary strategy are displayed by dots. Reference approach and
risk prediction model (2) within the sequential complementary strategy are
estimated by lasso. (PDF 36 kb)
Additional file 7: Boxplots of bootstrap 632+ prediction error estimates
of the linking model for varying overlap sizes (first AML application
example). Boxplots of bootstrap 632+ prediction error estimates of the
linking model (3) from single resampling data sets conditioning on the
decreased overlap sizes. (PDF 34 kb)
Additional file 8: Variability of the .632+ prediction error estimates in the
first AML data application example (swapped order). Boxplots of the
integrated prediction error curve estimates for the Cox model, the SNP
model and the sequential complementary strategy (swapped order).
(PDF 35 kb)
Additional file 9: R code. This R-file provides the underlying R code to
reproduce the results of the first AML application example combining SNP
and microarray-based gene expression data. (R 33 kb)
Acknowledgments
We gratefully acknowledge the support from the Willhelm-Sander
Foundation. The article processing charge was funded by the German
Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the
funding programme Open Access Publishing.
Funding
Position of SH has partially been funded by the Willhelm Sander foundation.
Availability of data andmaterials
The datasets supporting the conclusions of this article are included within the
Additional files (first AML application example combining SNP and
microarray-based gene expression data) and are available from the TCGA
repository https://tcga-data.nci.nih.gov/tcga/ (second AML application
example combining methylation and gene expression sequencing data). The
underlying R code to reproduce the results of the first AML application
example is given in Additional file 9.
Authors’ contributions
SH developed the proposed strategy and applied this to the example data,
and drafted the manuscript. AB, MS and HB contributed design decisions for
the strategy and helped with the interpretation of the results for the example
data. HB helped to draft the manuscript. RFS and LB acquired the data,
provided the biological background and contributed in discussions. All




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable as data example is re-analysis of publicly available data.
Author details
1Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical
Center - University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg, Germany.
2Freiburg Center for Data Analysis and Modeling, University Freiburg, Eckerstr.
1, 79104 Freiburg, Germany. 3Division of Biostatistics, German Cancer Research
Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. 4Department
of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23,
89081 Ulm, Germany. 5Institute of Medical Biostatistics, Epidemiology and
Informatics, University Medical Center Johannes Gutenberg University Mainz,
Obere Zahlbacher Str. 69, 55131 Mainz, Germany.
Received: 11 September 2015 Accepted: 12 August 2016
References
1. Tibshirani R. 58. J R Stat Soc Ser B Methodol. 1996267–88.
2. Binder H, Schumacher M. Allowing for mandatory covariates in boosting
estimation of sparse high-dimensional survival models. BMC Bioinforma.
2008;9(14).
3. Bullinger L, Kroenke J, Schoen C, et al. Identification of Acquired Copy
Number Alterations and Uniparental Disomies in Cytogenetically Normal
Acute Myeloid Leukemia Using High-Resolution Single Nucleotide
Polymorphism Analysis. Leukemia. 2010;24:438–49.
4. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to
identify prognostic subclasses in adult acute myeloid leukemia. N Engl J
Med. 2004;350(16):1605–16.
5. Kharas M, Lengner C, Al-Shahrour F, et al. Musashi-2 regulates normal
hematopoiesis and accelerates leukemogenesis. Nat Med. 2010;16:903–8.
6. Tutz G, Binder H. Boosting ridge regression. Comput Stat Data Anal.
2007;51(12):6044–59. http://dx.doi.org/10.1016/j.csda.2006.11.041.
7. Kirk P, Griffin J, Savage R, Ghahramani Z, Wild D. Bayesian correlated
clustering to integrate multiple datasets. Bioinformatics. 2012;28(24):
3290–7.
8. Witten D, Tibshirani R, Hastie T. A Penalized Matrix Decomposition, with
Applications to Sparse Principal Components and Canonical Correlation
Analysis. Biostatistics. 2009;10(3):515–34.
9. van Deun K, Wilderjans T, van den Berg R, Antoniadis A, Mechelen IV. A
flexible framework for sparse simultaneous component based data
integration. BMC Bioinforma. 2011;12:448.
10. Bullinger L, Rücker F, Kurz S, et al. Gene-expression profiling identifies
distinct subclasses of core binding factor acute myeloid leukemia. Blood.
2007;110(4):1291–300.
11. Cox DR. Regression Models and Life-tables (with Discussion). J R Stat Soc
Ser B Methodol. 1972;34:187–220.
12. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line
Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature. 2012;483:603–7.
13. Schwender H, Ruczinski I, Ickstadt K. Testing SNPs and sets of SNPs for
importance in association studies. Biostatistics. 2011;12:18–32.
14. Efron B, Tibshirani R. Improvements on Cross-Validation: The.632+
Bootstrap Method. J Am Stat Assoc. 1997;92(438):548–60.
Hieke et al. BMC Bioinformatics  (2016) 17:327 Page 13 of 13
15. Sauerbrei W, Boulesteix A, Binder H. Stability investigations of
multivariable regression models derived from low- and high-dimensional
data. J Biopharm Stat. 2011;21(6):1206–31.
16. Sauerbrei W, Buchholz A, Boulesteix A-L, Binder H. On stability issues in
deriving multivariable regression models. Biom J. 2015;57:531–55.
doi:10.1002/bimj.201300222.
17. Meinshausen N, Bühlmann P. Stability selection. J R Stat Soc Ser B Stat
Methodol. 2010(72):417–73.
18. Binder H, Schumacher M. Adapting Prediction Error Estimates for Biased
Complexity Selection in High-Dimensional Bootstrap Samples. Stat Appl
Genet Mol Biol. 2008;7:12. doi:10.2202/1544-6115.1346, http://www.
bepress.com/sagmb/vol7/iss1/art12.
19. Brier GW. Verification of forecasts expressed in terms of probability. Mon
Weather Rev. 1950;78:1–3.
20. Gerds TA, Schumacher M. Efron-type measures of prediction error for
survival analysis. Biometrics. 2007;63(4):1283–7. http://dx.doi.org/10.1111/
j.1541-0420.2007.00832.x.
21. Schumacher M, Binder H, Gerds T. Assessment of Survival Prediction
Models Based on Microarray Data. Bioinformatics. 2007;23(14):1768–74.
22. Du P, Zhang X, Huang CC, et al. Comparison of Beta-value and M-value
methods for quantifying methylation levels by microarray analysis. BMC
Bioinforma. 2010;11:587.
23. Anders S, Huber W. Differential expression analysis for sequence count
data. Genome Biol. 2010;11:R106. http://genomebiology.com/2010/11/
10/R106/.
24. Zwiener I, Frisch B, Binder H. Transforming RNA-Seq Data to Improve the
Performance of Prognostic Gene Signatures. PLoS ONE. 2014;9:e85150.
doi:10.1371/journal.pone.0085150, http://dx.doi.org/10.1371%2Fjournal.
pone.0085150.
25. Pericole F, Machado-Neto J, Costa F, Saad S. Abnormal Expression of
Ndfip2 and Cbl in Acute Myeloid Leukemia and Myelodysplastic
Syndrome Patients: Role of Ubiquitin Proteasome System in Myeloid
Neoplasms and Normal Hematopoiesis [abstrcat]. Blood. 2011;118:s2567.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
